Efficacy and Safety of Jiawei Suanzaoren Decoction Combined with Lorazepam for Chronic Insomnia: A Parallel-Group Randomized Controlled Trial

Abstract EN

Background.

Chronic insomnia is a major public health problem, but there are limited effective therapies.

Jiawei Suanzaoren Decoction (JW-SZRD) has been used as an alternative option for treating insomnia.

This study aimed to investigate the long-term efficacy and safety of JW-SZRD in combination with lorazepam for chronic insomnia.

Methods.

A total of 207 participants were analyzed in this study.

The treatment group (TG) received JW-SZRD and lorazepam orally, and the control group (CG) received lorazepam alone.

The Insomnia Severity Index (ISI), the Self-Rating Depression Scale (SDS), the Self-Rating Anxiety Scale (SAS), and the Somatic Self-rating Scale (SSS) were evaluated at baseline, weeks 4, 8, and 12.

The MOS 36-item Short Form Health Survey (SF-36) was assessed at baseline and week 12.

Adverse effects (AEs) were evaluated by the Treatment Emergent Symptom Scale (TESS).

Results.

Both TG and CG showed obvious improvements in the sleep onset latency (SOL) (P=0.001 and 0.005) and total sleep time (TST) (P=0.0001 and 0.001).

However, TG was more effective than CG at weeks 8 (P=0.02 for SOL, P=0.008 for TST) and 12 (P=0.03 for SOL, P=0.04 for TST), especially in shortening SOL (Cohen’s d = 1.28).

The ISI reduction rate in TG was higher than that in CG at weeks 4, 8, and 12 (P=0.008, 0.001 and 0.001).

After treatment, TG had lower SAS scores (P=0.0001, 0.007), less somatic symptoms (P<0.05 or 0.01), higher SF-36 scores (P<0.05 or 0.01), better compliance (P=0.0001), and less adverse effects (P<0.05 or 0.01) than those in CG.

Conclusion.

The combination of JW-SZRD with lorazepam can significantly improve sleep quality with fewer AEs.

It is an effective treatment and superior to lorazepam alone for chronic insomnia.